Truist analyst Michael Lewis downgraded Sabra Health Care (SBRA) to Hold from Buy with a price target of $17, down from $18. The firm cites relative valuation for the downgrade, after the stock was up 31% last year vs. 9% for REITs overall. While Sabra Health Care REIT is still a little cheaper than some of its peers, Truist projects slightly below average FFO and FAD growth over the next three- and five-year periods, and thinks there may be better opportunities elsewhere, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: